Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TACE in Radical Surgery for Hepatocellular Carcinoma With High-risk Recurrence Factors
NCT07417397Phase 3Recruiting
- Sponsor
- Guangxi Medical University
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of lobaplatin, ethiodized oil in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Started Feb 2026; status: recruiting.
02
Drugs
lobaplatinethiodized oil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07417397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417397.